Abstract:FXS is the most common genetic cause of intellectual (ID) and autism spectrum disorders (ASD). FXS is caused by loss of FMRP, an RNA-binding protein involved in the translational regulation of a large number of neuronal mRNAs. Absence of FMRP has been shown to lead to elevated protein synthesis and is thought to be a major cause of the synaptic plasticity and behavioural deficits in FXS. The increase in protein synthesis results in part from abnormal activation of key protein translation pathways downstream of ERK1/2 and mTOR signalling. Pharmacological and genetic interventions that attenuate hyperactivation of these pathways can normalize levels of protein synthesis and improve phenotypic outcomes in animal models of FXS. Several efforts are currently underway to trial this strategy in patients with FXS. To date, elevated global protein synthesis as a result of FMRP loss has not been validated in the context of human neurons. Here, using an isogenic human stem cell-based model, we show that de novo protein synthesis is elevated in FMRP-deficient neural cells. We further show that this increase is associated with elevated ERK1/2 and Akt signalling and can be rescued by metformin treatment. Finally, we examined the effect of normalizing protein synthesis on phenotypic abnormalities in FMRP-deficient neural cells. We find that treatment with metformin attenuates the increase in proliferation of FMRP-deficient neural progenitor cells but not the neuronal deficits in neurite outgrowth. The elevated level of protein synthesis and the normalization of neural progenitor proliferation by metformin treatment were validated in additional control and FXS patient-derived hiPSC lines. Overall, our results validate that loss of FMRP results in elevated de novo protein synthesis in human neurons and suggest that approaches targeting this abnormality are likely to be of partial therapeutic benefit in FXS.

Novel presynaptic assay system revealed that metformin ameliorates exaggerated synaptic release and Munc18-1 accumulation in presynapses of neurons from Fragile X syndrome mouse model

Metformin ameliorates core deficits in a mouse model of fragile X syndrome

Early metformin treatment: An effective approach for targeting fragile X syndrome pathophysiology

Elevated de novo protein synthesis in FMRP-deficient human neurons and its correction by metformin treatment

The safety and efficacy of metformin in fragile X syndrome: An open-label study

Metformin for Treatment of Fragile X Syndrome and Other Neurological Disorders

Adiponectin rescues synaptic plasticity in the dentate gyrus of a mouse model of Fragile X Syndrome

Developmental Impairments of Synaptic Refinement in the Thalamus of a Mouse Model of Fragile X Syndrome

Reduction of Fmr1 mRNA Levels Rescues Pathological Features in Cortical Neurons in a Model of FXTAS

Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes

Inhibition of GluN2A NMDA receptors ameliorates synaptic plasticity deficits in the Fmr1-/y mouse model

Fragile X Syndrome Patient–Derived Neurons Developing in the Mouse Brain Show FMR1-Dependent Phenotypes

An iPSC model of fragile X syndrome reflects clinical phenotypes and reveals m6A-mediated epi-transcriptomic dysregulation underlying synaptic dysfunction

Metformin treatment in young children with fragile X syndrome

Modeling Fragile X Syndrome: Characterizing Fmr1 Gene Knockout Mice across Genotype, Behavior, and Morphology

Proteomics insights into fragile X syndrome: Unraveling molecular mechanisms and therapeutic avenues

mGluR7 allosteric modulator AMN082 corrects protein synthesis and pathological phenotypes in FXS

Translational modulator ISRIB alleviates synaptic and behavioral phenotypes in Fragile X syndrome

Blood-Based Biomarkers Predictive of Metformin Target Engagement in Fragile X Syndrome

Early 7,8-Dihydroxyflavone Administration Ameliorates Synaptic and Behavioral Deficits in the Young FXS Animal Model by Acting on BDNF-TrkB Pathway

Cognitive and behavioral improvement in adults with fragile X syndrome treated with metformin-two cases